Corline Biomedical AB (STO:CLBIO)
Sweden
· Delayed Price · Currency is SEK 15.65
-0.25 (-1.57%)
Mar 9, 2026, 5:29 PM CET
Corline Biomedical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 8.59 | 17.27 | 35.52 | 32.59 | 17.19 | Upgrade
|
| Revenue Growth (YoY) | -50.29% | -51.37% | 8.98% | 89.55% | 14.05% | Upgrade
|
| Cost of Revenue | 2.36 | 3.83 | 7.14 | 9.87 | 8.09 | Upgrade
|
| Gross Profit | 6.23 | 13.44 | 28.38 | 22.73 | 9.1 | Upgrade
|
| Selling, General & Admin | 20.35 | 26.93 | 28.74 | 20.89 | 15.95 | Upgrade
|
| Other Operating Expenses | 0.58 | - | 1.74 | -0.55 | 0.03 | Upgrade
|
| Operating Expenses | 21.01 | 27.03 | 30.58 | 20.4 | 16.01 | Upgrade
|
| Operating Income | -14.79 | -13.59 | -2.2 | 2.33 | -6.91 | Upgrade
|
| Interest Expense | -0 | -0.03 | -0.03 | - | -0.01 | Upgrade
|
| Interest & Investment Income | 0.04 | 0 | 0.01 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.41 | 0.41 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -14.71 | -13.2 | -1.81 | 2.33 | -6.92 | Upgrade
|
| Asset Writedown | - | -9.99 | - | - | - | Upgrade
|
| Pretax Income | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 | Upgrade
|
| Net Income | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 | Upgrade
|
| Net Income to Common | -14.71 | -23.19 | -1.81 | 2.33 | -6.92 | Upgrade
|
| Shares Outstanding (Basic) | 25 | 22 | 21 | 21 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 22 | 21 | 22 | 20 | Upgrade
|
| Shares Change (YoY) | 13.40% | 1.49% | -2.19% | 7.50% | 22.58% | Upgrade
|
| EPS (Basic) | -0.59 | -1.06 | -0.08 | 0.11 | -0.34 | Upgrade
|
| EPS (Diluted) | -0.59 | -1.06 | -0.08 | 0.11 | -0.34 | Upgrade
|
| Free Cash Flow | -17.74 | -8.64 | 0.75 | -6.61 | -4.98 | Upgrade
|
| Free Cash Flow Per Share | -0.72 | -0.40 | 0.04 | -0.30 | -0.24 | Upgrade
|
| Gross Margin | 72.51% | 77.82% | 79.90% | 69.73% | 52.94% | Upgrade
|
| Operating Margin | -172.20% | -78.67% | -6.20% | 7.15% | -40.18% | Upgrade
|
| Profit Margin | -171.37% | -134.29% | -5.09% | 7.15% | -40.26% | Upgrade
|
| Free Cash Flow Margin | -206.57% | -50.02% | 2.12% | -20.27% | -28.93% | Upgrade
|
| EBITDA | -14.68 | -13.49 | -2.1 | 2.39 | -6.88 | Upgrade
|
| EBITDA Margin | -170.99% | -78.12% | -5.92% | 7.32% | -40.00% | Upgrade
|
| D&A For EBITDA | 0.1 | 0.1 | 0.1 | 0.06 | 0.03 | Upgrade
|
| EBIT | -14.79 | -13.59 | -2.2 | 2.33 | -6.91 | Upgrade
|
| EBIT Margin | -172.20% | -78.67% | -6.20% | 7.15% | -40.18% | Upgrade
|
| Revenue as Reported | 8.62 | 17.69 | 35.93 | 33.33 | 17.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.